Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines,
Hidden Dangers of Compounded Weight-Loss Drugs
A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often misleading users about FDA approval. Researchers identified over 70 websites with vague safety disclosures.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.
8d
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
1d
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
3d
Outgoing FDA chief flags online weight loss drug dangers
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
6d
Eli Lilly's weight loss pill could get federal approval by early next year
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
2d
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
1d
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Seeking Alpha
12d
FDA issues draft guidance on developing weight loss drugs
The U.S.
FDA
has released a new draft guidance ... adding no CV signals have been observed with that
drug
. Two of the most prescribed
drugs
for
weight
loss
are GLP-1s: Novo Nordisk's (NVO) ...
BioSpace
11d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
HealthDay on MSN
11d
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
The Express Tribune
2d
Zyn nicotine pouches, dubbed 'Gen Z’s weight loss secret,' secure FDA approval
Zyn gains cult status among Gen Z, praised for boosting workouts, alertness, and dubbed O-Zyn-pic for weight loss.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback